These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28325713)

  • 1. Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011.
    Bikdeli B; Punnanithinont N; Akram Y; Lee I; Desai NR; Ross JS; Krumholz HM
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28325713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials.
    Bikdeli B; Caraballo C; Welsh J; Ross JS; Kaul S; Stone GW; Krumholz HM
    Clin Trials; 2020 Dec; 17(6):723-728. PubMed ID: 32838556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials.
    Patel RB; Vaduganathan M; Samman-Tahhan A; Kalogeropoulos AP; Georgiopoulou VV; Fonarow GC; Gheorghiade M; Butler J
    Am J Cardiol; 2016 Jun; 117(11):1845-50. PubMed ID: 27085935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate endpoints in randomized cardiovascular clinical trials.
    Domanski M; Pocock S; Bernaud C; Borer J; Geller N; Revkin J; Zannad F
    Fundam Clin Pharmacol; 2011 Aug; 25(4):411-3. PubMed ID: 20698890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian adaptive trial design for a newly validated surrogate endpoint.
    Renfro LA; Carlin BP; Sargent DJ
    Biometrics; 2012 Mar; 68(1):258-67. PubMed ID: 21838811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel procedures for validating surrogate endpoints in clinical trials.
    Cleophas TJ; Zwinderman AH; Chaib AH
    Curr Clin Pharmacol; 2007 May; 2(2):123-8. PubMed ID: 18690859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals.
    Tan NS; Ali SH; Lebovic G; Mamdani M; Laupacis A; Yan AT
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28954803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of funding source on effect size in randomized controlled trials: 2013-2015 - a cross-sectional survey and meta-analysis.
    Falk Delgado A; Falk Delgado A
    Trials; 2017 Mar; 18(1):125. PubMed ID: 28292317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decade-Long Profile of Imaging Biomarker Use in Ophthalmic Clinical Trials.
    Villani E; Massaro D; Scaramuzzi M; Hamrah P; Medeiros FA; Nucci P
    Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO76-BIO81. PubMed ID: 28525561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
    Methy N; Bedenne L; Bonnetain F
    BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.
    Ridker PM; Torres J
    JAMA; 2006 May; 295(19):2270-4. PubMed ID: 16705108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate endpoint analysis: an exercise in extrapolation.
    Baker SG; Kramer BS
    J Natl Cancer Inst; 2013 Mar; 105(5):316-20. PubMed ID: 23264679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate markers as surrogate endpoints in cancer research.
    Schatzkin A
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endpoint selection and relative (versus absolute) risk reporting in published medication trials.
    Hochman M; McCormick D
    J Gen Intern Med; 2011 Nov; 26(11):1246-52. PubMed ID: 21842324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive probability of success using surrogate endpoints.
    Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
    Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.
    Wittkop L; Smith C; Fox Z; Sabin C; Richert L; Aboulker JP; Phillips A; Chêne G; Babiker A; Thiébaut R;
    Clin Trials; 2010 Feb; 7(1):19-35. PubMed ID: 20156955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of endpoint characteristics in periodontal clinical trials published 1988-1992, and implications for future studies.
    Hujoel PP; DeRouen TA
    J Clin Periodontol; 1995 May; 22(5):397-407. PubMed ID: 7601922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound and radiology surrogate endpoints in pharmacological studies.
    Agewall S; DeGroot E; Marcos-Alberca P; Zamorano JL; Barrero AA; Badano LP; Perrone-Filardi P
    Atherosclerosis; 2012 Sep; 224(1):12-24. PubMed ID: 22632921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.